Lanean...

Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition

PARP inhibitor monotherapies are effective to treat patients with breast, ovary, prostate, and pancreatic cancer with BRCA1 mutations, but not to the much more frequent BRCA wild-type cancers. Searching for strategies that would extend the use of PARP inhibitors to BRCA1-proficient tumors, we found...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Luo, Man-Li, Zheng, Fang, Chen, Wenying, Liang, Zhi-Mei, Chandramouly, Gurushankar, Tan, Jianan, Willis, Nicholas A., Chen, Chun-Hau, Taveira, Mateus de Oliveira, Zhou, Xiao Zhen, Lu, Kun Ping, Scully, Ralph, Wulf, Gerburg M., Hu, Hai
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7755124/
https://ncbi.nlm.nih.gov/pubmed/32193285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-2739
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!